, Volume 5, Issue 2, pp 149-153
Date: 17 Mar 2009

Recent Advances Toward the Clinical Application of PTH (1-34) in Fracture Healing

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

One or more of the authors (JML) has received funding from (Eli Lilly)